Navigation Links
NPS Pharmaceuticals and Nycomed Announce Licensing Agreement for GATTEX(TM) in Territories Outside North America
Date:9/26/2007

ications for GATTEX.

A potential first-in-class drug, GATTEX is a proprietary analog of naturally occurring human glucagon-like peptide 2 (GLP-2), a peptide secreted primarily in the distal intestine and involved in the regeneration and repair of the intestinal epithelium. A previous Phase 2 proof-of-concept clinical study in patients with SBS showed that daily subcutaneous injections of GATTEX resulted in significant growth of the intestinal lining and improved dietary absorption of nutrients and fluids. Once the company has completed its analysis of data from the Phase 3 SBS study, it expects to pursue a pre-NDA meeting with the U.S. Food and Drug Administration to discuss its potential plan for submitting a New Drug Application in mid-2008. NPS is also pursuing development of GATTEX as a possible treatment for chemotherapy-induced gastrointestinal mucositis in cancer patients and necrotizing enterocolitis in preterm infants.

NPS president and CEO Dr. Tony Coles stated, "This agreement expands our relationship with Nycomed and brings us an important strategic partner for GATTEX outside North America. The collaboration provides us with a partner that will help us pursue a full development program for GATTEX worldwide, not only in SBS, but potentially in other indications, as well. We welcome this opportunity to collaborate with Nycomed to advance GATTEX in these key territories and look forward to our work together on realizing the full potential of this unique compound."

Nycomed CEO Hakan Bjorklund stated, "We believe GATTEX has the potential to be an important new therapy for serious gastrointestinal conditions. We are excited to add GATTEX to our product pipeline, as it perfectly matches our development and marketing capabilities in the gastroenterology field. We look forward to developing GATTEX as a partner of NPS."

Nycomed markets Preotact(R) (parathyroid hormone for injection) in the European Union under license from NPS and has right
'/>"/>

SOURCE NPS Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Supply of Radiopharmaceuticals Hampered by Attacks
2. FDA approves Watson Pharmaceuticals Oxytrol patch
3. Ranbaxy Pharmaceuticals Inc awarded the prestigious outstanding supplier award received from Wal-Mart
4. Antigenics Pharmaceuticals plans for Phase III trial of its Melanoma vaccine
5. United Kingdom Is Lagging In Novelty In The Field Of Pharmaceuticals
6. Top Pharmaceuticals Influence Doctors Prescriptions
7. More Study On Side Effects of ADHD Drug Needed: Shire Pharmaceuticals
8. Personalized Medicine and Innovative Pharmaceuticals
9. New lease of life for asthmatics by Accentia Biopharmaceuticals
10. Pravastatin Launched by Watson Pharmaceuticals
11. Tata Industries picks up stake in Indigene Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... ... 2015 , ... Cs &A, the leader in Semi Timing ... and publication of their newest offering to complement the existing line of Market ... Designed in support of coverage for the full spectrum of Semi Timing solutions ...
(Date:7/2/2015)... Chicago (PRWEB) , ... July 02, 2015 , ... ... companies innovate across their products, services, channels and business models. To help manage ... is announcing the addition of Mark Benkendorf as SVP of Strategic Engagements. , ...
(Date:7/1/2015)... CA (PRWEB) , ... July 01, 2015 , ... In ... great outdoors. Yet, in many Middle-Eastern countries like Saudi Arabia and Dubai, the summer ... relax in more temperate climates. Celebrity dentist Dr. Sam Saleh of ORA Dentistry Spa ...
(Date:7/1/2015)... ... 2015 , ... Dr. Jian-Dong Li, a professor and director ... Research Alliance Eminent Scholar in Inflammation and Immunity, has received a five-year, $1.6 ... grant from the National Institute on Deafness and Other Communication Disorders of the ...
(Date:7/1/2015)... (PRWEB) , ... July 01, 2015 , ... ... against the manufacturers of Levaquin ( http://www.injurybeacon.com/levaquin/lawsuit/ ) has granted the Defendants’ Motion ... Southern District of West Virginia on June 26th, the Court rejected the Plaintiff’s ...
Breaking Medicine News(10 mins):Health News:Cs &A Releases the SEMI TIMING Newsletter Specific to the Semiconductor Timing Industry 2Health News:Cs &A Releases the SEMI TIMING Newsletter Specific to the Semiconductor Timing Industry 3Health News:Cs &A Releases the SEMI TIMING Newsletter Specific to the Semiconductor Timing Industry 4Health News:Business Builder Mark Benkendorf Joins Innovation Firm Maddock Douglas 2Health News:Dr. Sam Saleh Invites Vacationing International Patients to Get a Same-Day Hollywood Smile During the July Travel Season 2Health News:Institute for Biomedical Sciences Researcher Gets $1.6 Million to Develop Anti-Inflammatory Drug 2Health News:Levaquin Lawsuit Attorneys at Bernstein Liebhard LLP Comment on Decision to Grant Summary Judgment in Generic Drug Case 2Health News:Levaquin Lawsuit Attorneys at Bernstein Liebhard LLP Comment on Decision to Grant Summary Judgment in Generic Drug Case 3
... Inc. (Nasdaq: VNUS ), a leading provider of ... disease, today,announced that it presented at the William Blair ... on October 3, 2007, at the New York,Palace Hotel ... the VNUS presentation webcast is available on the,corporate website ...
... SAN DIEGO, Oct. 3 Anadys Pharmaceuticals,Inc. (Nasdaq: ... BIO,InvestorForum 2007 on Wednesday, October 10, 2007, at 11:45 ... at The Palace Hotel in San,Francisco. Steve Worland, ... will present an overview of Anadys and an update ...
... A new Web site from Northwood,Health Systems has ... a five-year development effort in partnership with the best,Web ... perfect the,application of Web site technology," Northwood President and ... http://www.NorthwoodHealth.com, offers more than 1,000 accredited,continuing education courses ...
... NORCROSS, Ga., Oct. 3 Immucor, Inc. (Nasdaq:,BLUD), ... to,the blood transfusion industry, today reported financial results ... Revenue for the fiscal first quarter was ... in the same period last year. Of the ...
... Oct. 3 The patent lawsuit,by VNUS(R) Medical Technologies, ... Diomed, AngioDynamics and Vascular Solutions,is set to proceed to ... by both sides. In its motions VNUS had asked ... infringed the VNUS patents,while the defendants countered with their ...
... will work, experts say , WEDNESDAY, Oct. 3 (HealthDay ... help doctors determine the best chemotherapy for patients, U.S. ... tumors would be most likely to respond to standard ... has traditionally been a second-line therapy, based on gene ...
Cached Medicine News:Health News:Anadys Pharmaceuticals to Present at BIO InvestorForum 2007 2Health News:Immucor Announces Record Fiscal First Quarter Revenues 2Health News:Immucor Announces Record Fiscal First Quarter Revenues 3Health News:Immucor Announces Record Fiscal First Quarter Revenues 4Health News:Immucor Announces Record Fiscal First Quarter Revenues 5Health News:Immucor Announces Record Fiscal First Quarter Revenues 6Health News:Immucor Announces Record Fiscal First Quarter Revenues 7Health News:Immucor Announces Record Fiscal First Quarter Revenues 8Health News:VNUS Medical's Patent Lawsuit Against Laser Competitors to Proceed to Trial 2Health News:VNUS Medical's Patent Lawsuit Against Laser Competitors to Proceed to Trial 3Health News:Gene Tests Match Up Lung Tumors, Best Treatment 2
(Date:7/2/2015)... DUBLIN , June 25, 2015 /PRNewswire/ ... http://www.researchandmarkets.com/research/8mfjxh/2015_new ) has announced the addition of ... Chemistry and Immunodiagnostics: Global Challenges, Emerging Technologies, ... 2015 New Frontiers in Clinical ... Competitive Landscape is a new seven-country strategic ...
(Date:7/2/2015)...  Konica Minolta, Inc. (Konica Minolta) ( Tokyo ... Sawae Technologica Ltda., an X-ray system equipment manufacturer based ... its Brazilian healthcare sales company, Konica Minolta Healthcare do ... Brazil market investment and growth With ... million, significant healthcare technical advancements and efficiencies are required. ...
(Date:7/2/2015)... , 2. Juli 2015 BGI gab ... in Hongkong vom American College of Pathologists ... ist das erste klinische Next-Generation-Sequencing Labor, das ... CAP-Zertifkat erhält und somit die höchsten Standards ... bestehenden US FDA - 21 CFR Part ...
Breaking Medicine Technology:New Frontiers in 2015 Global Clinical Chemistry and Immunodiagnostics Market: Challenges, Emerging Technologies, Competitive Landscape 2Konica Minolta Acquires Sawae, Enhancing Digital X-ray Diagnostic Imaging Systems in Brazil 2Konica Minolta Acquires Sawae, Enhancing Digital X-ray Diagnostic Imaging Systems in Brazil 3BGI erhält Akkreditierung vom College of American Pathologists (CAP) 2
... YINCHUAN, China , July ... Nie Wentao,s nutrition intervention technology for type 1,diabetes mellitus. ... technology for diabetes treatment, so it aroused widespread,concern in ... the study of nutrition,interventions on diabetes mellitus for a ...
... July 14 Osseon Therapeutics, Inc., a biomedical ... received a notice of allowance for its spinal vertebral compression ... has thirteen additional patent applications pending in the United ... and devices. The lead inventor for this inaugural patent is ...
Cached Medicine Technology:Dr. Nie Wentao's New Method of Diabetic Nutrition Interventions 2Dr. Nie Wentao's New Method of Diabetic Nutrition Interventions 3Dr. Nie Wentao's New Method of Diabetic Nutrition Interventions 4Dr. Nie Wentao's New Method of Diabetic Nutrition Interventions 5Osseon Receives Patent Allowance for Novel Spinal VCF Treatment Devices 2
HST, multi frequency Side Fire "T intraoperative transducer. A wide field of view is this transducers benefit....
Super High Density, 120 field of view, angled handle, multi-frequency, convex endovaginal transducer....
Provides tremendous image quality along with a 180 degree field of view....
Prostate biopsy transducer....
Medicine Products: